Shopping Cart 0
Cart Subtotal
USD 0

Acceleron Pharma Inc (XLRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Acceleron Pharma Inc (Acceleron Pharma) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics to treat serious and rare diseases. The company's lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodysplastic syndromes, beta-thalassemia and myelofibrosis. It also offers pipeline products for the treatment of facioscapulohumeral muscular dystrophy, neuromuscular diseases, renal cell carcinoma and other indications. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc (XLRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11

Adimab Enters into Agreement with Acceleron Pharma 12

Licensing Agreements 13

Acceleron Pharma Enters into Licensing Agreement with Celgene 13

Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15

Equity Offering 16

Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16

Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18

Acceleron Pharma Completes Public Offering Of Shares For USD 138 Million 20

Acceleron Pharma Completes IPO For USD 96.3 Million 22

Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 24

Acceleron Pharma Inc-Key Competitors 26

Acceleron Pharma Inc-Key Employees 27

Acceleron Pharma Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Oct 30, 2018: Acceleron reports third quarter 2018 operating and financial results 29

Aug 02, 2018: Acceleron reports second quarter 2018 operating and financial results 31

May 08, 2018: Acceleron Reports First Quarter 2018 Operating and Financial Results 33

Feb 27, 2018: Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results 35

Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 37

May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 39

Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 41

Corporate Communications 43

Jul 05, 2018: Acceleron Names Robert K. Zeldin, M.D., Chief Medical Officer 43

Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 44

May 02, 2017: Acceleron Announces Management Change 45

Product News 46

11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 46

07/05/2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer 47

02/08/2018: Acceleron Announces Appointment of Chief Commercial Officer 48

Clinical Trials 49

Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia 49

Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes 50

Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association 51

Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting 52

May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association 53

Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting 54

Jan 03, 2018: Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman 55

Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology 56

Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 58

Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 59

Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 60

Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 61

Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 62

Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 63

Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 64

Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 66

Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 68

May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 69

May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 70

Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 72

Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 73

Other Significant Developments 74

Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 74

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11

Adimab Enters into Agreement with Acceleron Pharma 12

Acceleron Pharma Enters into Licensing Agreement with Celgene 13

Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15

Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16

Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18

Acceleron Pharma Completes Public Offering Of Shares For USD 138 Million 20

Acceleron Pharma Completes IPO For USD 96.3 Million 22

Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 24

Acceleron Pharma Inc, Key Competitors 26

Acceleron Pharma Inc, Key Employees 27

Acceleron Pharma Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Acceleron Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Acceleron Pharma Inc (Acceleron Pharma) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics to treat serious and rare diseases. The company's lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodysplastic syndromes, beta-thalassemia and myelofibrosis. It also offers pipeline products for the treatment of facioscapulohumeral muscular dystrophy, neuromuscular diseases, renal cell carcinoma and other indications. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc (XLRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11

Adimab Enters into Agreement with Acceleron Pharma 12

Licensing Agreements 13

Acceleron Pharma Enters into Licensing Agreement with Celgene 13

Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15

Equity Offering 16

Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16

Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18

Acceleron Pharma Completes Public Offering Of Shares For USD 138 Million 20

Acceleron Pharma Completes IPO For USD 96.3 Million 22

Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 24

Acceleron Pharma Inc-Key Competitors 26

Acceleron Pharma Inc-Key Employees 27

Acceleron Pharma Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Oct 30, 2018: Acceleron reports third quarter 2018 operating and financial results 29

Aug 02, 2018: Acceleron reports second quarter 2018 operating and financial results 31

May 08, 2018: Acceleron Reports First Quarter 2018 Operating and Financial Results 33

Feb 27, 2018: Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results 35

Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 37

May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 39

Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 41

Corporate Communications 43

Jul 05, 2018: Acceleron Names Robert K. Zeldin, M.D., Chief Medical Officer 43

Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 44

May 02, 2017: Acceleron Announces Management Change 45

Product News 46

11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 46

07/05/2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer 47

02/08/2018: Acceleron Announces Appointment of Chief Commercial Officer 48

Clinical Trials 49

Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia 49

Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes 50

Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association 51

Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting 52

May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association 53

Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting 54

Jan 03, 2018: Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman 55

Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology 56

Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 58

Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 59

Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 60

Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 61

Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 62

Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 63

Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 64

Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 66

Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 68

May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 69

May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 70

Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 72

Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 73

Other Significant Developments 74

Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 74

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acceleron Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11

Adimab Enters into Agreement with Acceleron Pharma 12

Acceleron Pharma Enters into Licensing Agreement with Celgene 13

Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15

Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16

Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18

Acceleron Pharma Completes Public Offering Of Shares For USD 138 Million 20

Acceleron Pharma Completes IPO For USD 96.3 Million 22

Acceleron Pharma Completes Private Placement Of Shares For USD 10 Million 24

Acceleron Pharma Inc, Key Competitors 26

Acceleron Pharma Inc, Key Employees 27

Acceleron Pharma Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Acceleron Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.